Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

Summary

This is a randomized, double-blind, 2-arm, parallel group study of up to 274 evaluable patients designed to evaluate the safety and efficacy of the histone deacetylase 6 (HDAC6) inhibitor ricolinostat for painful DPN.

Timeline

Start

2020-12-07

Primary completion

2022-10-31

Completion

2023-04-28

Drugs

Indications